Lilly launches AI platform for biotechs with $1 billion worth of data

INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY), a pharmaceutical giant with a market capitalization of $663 billion and impressive revenue growth of 37% over the last twelve months, announced Tuesday the launch of Lilly TuneLab, an artificial intelligence and machine learning platform that gives biotech companies access to drug discovery models trained on Lilly’s research data.

The platform incorporates proprietary data that Lilly estimates cost over $1 billion to obtain, representing what the company describes as one of the industry’s most valuable datasets used to train an AI system available to biotechnology companies. This significant investment aligns with Lilly’s strong financial position, reflected in its industry-leading gross profit margin of 83% and "GREAT" financial health score according to InvestingPro analysis.

"Lilly TuneLab was created to be an equalizer so that smaller companies can access some of the same AI capabilities used every day by Lilly scientists," said Daniel Skovronsky, chief scientific officer and president of Lilly Research Laboratories and Lilly Immunology.

The platform is powered by Lilly’s drug disposition, safety, and preclinical datasets representing experimental data from hundreds of thousands of unique molecules. Selected biotech partners will contribute training data in exchange for access, which the company says will fuel continuous improvement of the system.

Lilly TuneLab employs federated learning, allowing biotechs to use Lilly’s AI models without directly exposing their proprietary data. The platform was developed through partnerships with technology providers and AI/ML experts.

This offering is the newest addition to Lilly Catalyze360’s services for biotech partners, which includes strategic capital, laboratory facilities, and drug development expertise.

According to the press release, Lilly plans to extend the platform’s capabilities in future releases, including adding in vivo small molecule predictive models that will be available exclusively on Lilly TuneLab.

Information about the platform is based on a company press release statement. For investors seeking deeper insights into Lilly’s AI initiatives and financial outlook, InvestingPro offers comprehensive analysis through its Pro Research Report, featuring detailed metrics and expert analysis of the company’s technological investments and growth strategy. The platform currently shows 15 additional investment tips for Lilly, available exclusively to subscribers.

In other recent news, Eli Lilly announced that its phase 3 trial of Jaypirca met the primary endpoint in patients with chronic lymphocytic leukemia. The results from the BRUIN CLL-313 and BRUIN CLL-314 trials are expected to support label expansions for the drug in earlier lines of therapy. Additionally, the company’s non-covalent BTK inhibitor Jaypirca showed statistically significant improvement in progression-free survival in treatment-naïve chronic lymphocytic leukemia patients compared to standard chemoimmunotherapy. In another development, the FDA has granted Breakthrough Therapy designation to Eli Lilly’s olomorasib, in combination with Keytruda, for specific lung cancer treatments. This designation applies to patients with unresectable advanced or metastatic non-small cell lung cancer with a KRAS G12C mutation and high PD-L1 expression. BMO Capital reiterated an Outperform rating on Eli Lilly, citing positive clinical trial results for its weight loss drug orforglipron. The ATTAIN-2 study demonstrated significant weight loss in obese patients with type 2 diabetes, paving the way for an FDA filing by year-end. These developments highlight Eli Lilly’s ongoing advancements in cancer and weight loss treatments.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.